« Return to News | Technology Solutions | Ethics/Regulatory

Nextrials Gets CDISC Approval

Wednesday, March 24, 2010 08:47 AM

Nextrials, a clinical research software and services company, has been approved by the Clinical Data Interchange Standards Consortium (CDISC) as one of 15 registered solutions providers. It is the only company offering an electronic data capture (EDC) product supporting the CDISC Healthcare Link Initiative.

Launched in 2005, the CDISC Healthcare Link Initiative focuses on the interoperability of electronic health records (EHR) platforms with EDC technology for clinical trials.

 “There are benefits to using an integrated EDC/EHR platform in the healthcare industry, and Nextrials should be applauded for its efforts in this arena,” stated Rebecca Kush, CDISC president and CEO. “By using a standards-based process, workflow for clinical research can be integrated into the workflow for clinical care. This streamlines the process for sharing clinical care information for multiple uses including research and public health. It promotes a reduction in time for data entry and increased data accuracy by eliminating transcription.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.